secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093356
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo posts Q2 net loss $5.9M, cash $8.1M; APVO436 Phase 1b/2 trial to begin
-----------------------------------------------------------------------------

- Net loss of $5.9M ($1.67/sh) vs $7.9M ($53.95/sh) in Q2 2023; R&D spend down 33% to $3.6M.
- Cash $8.1M at June 30; proforma $10.4M including $2.75M July direct offering, extending runway into 2025.
- APVO436 Phase 1b/2 dose optimization trial for AML expected to start in Q3 2024; prior expansion showed 91% clinical benefit rate.
- ALG.APV-527 solid-tumor trial >90% enrolled; data showed durable stable disease in two heavily pretreated breast cancer patients.
- Max tolerated dose not yet reached for ALG.APV-527; dosing continues in cohort five.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024093356/0000950170-24-093356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024093356/apvo-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer